Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

16-Week Randomized Double-Blind Placebo Controlled Parallel-Group Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day in Adolescents With Bilateral Nasal Polyps Followed With 12-Week Open-Label Treatment Phase

NCT03747458 is registered in ClinicalTrials.gov with Optinose US Inc. as lead sponsor.

NCT NCT03747458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03747458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
16-Week Randomized Double-Blind Placebo Controlled Parallel-Group Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day in Adolescents With Bilateral Nasal Polyps Followed With 12-Week Open-Label Treatment Phase
Lead sponsor
Optinose US Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2018
Completion date
June 11, 2026
Enrollment
40 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

bilateral nasal polyposis